Very high-magnification micrograph of Ewing sarcoma in the lung. Credit: Nephron.

Gradalis has started a Phase lll clinical trial of Vigil in combination with irinotecan and temozolomide for the treatment of patients with Ewing’s sarcoma (EWS).

The multicentre, randomised, open-label trial intends to analyse the study drug combination as a second-line regimen for EWS, a rare form of pediatric cancer that originates in bone or soft tissue.

Caused by genetic mutation, EWS is currently estimated to affect around 1,000 individuals across the globe every year.

The Phase lll trial is expected to enrol around 140 patients with metastatic Ewing’s sarcoma family of tumours (ESFT) refractory/intolerant or recurrent to one prior line of chemotherapy.

The enrolled patients will be randomised in 1:1 ratio to receive daily oral dose of temozolomide 100mg/m² and daily oral dose of irinotecan 50mg/m² for five days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

They will also receive Vigil 1.0 x 10e6 cells/injection cells/injection, intradermally on day 15.

“For patients affected by Ewing’s sarcoma, our most recent trial has shown positive results with minimal side effects.”

The trial’s primary endpoint is progression free survival (PFS), while its secondary endpoints include overall survival (OS) and radiological tumour assessment.

Gradalis chief medical officer John Nemunaitis said: “For patients affected by Ewing’s sarcoma, our most recent trial has shown positive results with minimal side effects.

“We believe Gradalis’ approach of exploiting the patient’s existing, highly adapted immune system by presenting the entire neoantigen matrix and induced T-cell responses against their cancer has great promise.”

In addition, Gradalis is conducting a number of other clinical studies for Vigil for the treatment of various types of cancer.

Vigil is currently being evaluated as a cellular immunotherapy technology that combines genetic engineering with immuno-oncology.